Kestra Medical Technologies (KMTS) Q4 2026: Gross Margin Expands 1,100bps, Accelerating Market Penetration
Kestra Medical Technologies delivered a standout Q4, expanding gross margin by 1,100 basis points and cementing its position as the high-growth disruptor in the wearable cardioverter defibrillator (WCD) market. With a strategic focus on commercial expansion and clinical evidence, Kestra is leveraging operating leverage and payer mix gains to drive durable growth. FY27 guidance signals confidence in continued share gains and market expansion, propelled by a broadened salesforce and accelerating adoption of the Assure system.
Summary
- Margin Expansion Surpasses Expectations: Volume leverage and payer mix drove ten consecutive quarters of gross margin gains.
- Salesforce Buildout Fuels Adoption: Territory count up 63%, activating new prescribers and deepening account penetration.
- Guidance Anchored in Durable Growth: FY27 outlook reflects confidence in continued share capture and scalable model economics.
Business Overview
Kestra Medical Technologies develops and commercializes the Assure wearable cardioverter defibrillator (WCD), a device designed to protect patients at risk of sudden cardiac arrest during post-hospital recovery. Revenue is generated through a rental model, where devices are prescribed by clinicians and reimbursed by payers. The business is structured around commercial sales, clinical evidence generation, revenue cycle management, and product innovation, with the Assure system as the flagship offering.
Performance Analysis
Kestra posted $28.6 million in Q4 revenue, up 66% year-over-year, driven by a 63% increase in Assure prescriptions. The full year delivered $95 million in revenue, marking 59% annual growth, with gross margin expanding to 54.8% in Q4 and 51.4% for the year. This 1,100bps annual margin expansion reflects the attractive unit economics of the rental business model and improved payer mix, as more patients were covered in-network and revenue cycle management (RCM) capabilities matured.
Operating leverage is emerging as a core theme, with operating cash burn declining year-over-year despite heavy investment in commercial headcount and RCM infrastructure. The company ended FY26 with 130 sales territories, up from 80, and a robust liquidity position of $357 million, bolstered by a new $200 million term loan facility. The prescription fill rate and collections also trended positively, supporting both top-line and margin expansion.
- Salesforce Expansion: Territory count grew 63% YoY, directly driving prescription volume and new account activation.
- Revenue Cycle Optimization: RCM investments and payer contracting increased in-network rates and collections efficiency.
- Clinical Evidence Impact: The ACE-PASS study and Heart Rhythm publication catalyzed prescriber adoption, supporting market expansion.
Kestra’s model is now showing clear scalability, with sequential gross margin gains and improved cash flow even as investments ramped. The company’s ability to convert commercial investment into durable revenue growth is a central investment thesis heading into FY27.
Executive Commentary
"We continue to reach more patients at risk of cardiac arrest, accepting over 6,300 prescriptions written for the Assure system. Revenue was $28.6 million with growth of 66% compared to the prior year period. For the year, Kestra generated $95 million of revenue, resulting in growth of 59% compared to FY25. Gross margin of 54.8% expanded by over 10 points year-over-year and 200 basis points sequentially, reflecting the attractive unit economics of our rental model. This was our 10th quarter in a row of sequential gross margin expansion."
Brian Webster, President and Chief Executive Officer
"As we continue to bring more payers in-network and enhance our revenue cycle management capabilities, we expect to see benefits in revenue growth, gross margin, and our profitability profile. We are investing in revenue cycle AI tools and other automation projects that will drive operating leverage as we scale the business."
Vaseem Mahboob, Chief Financial Officer
Strategic Positioning
1. Commercial Expansion and Market Penetration
Kestra’s field team grew from 80 to 130 active sales territories in FY26, expanding geographic coverage to roughly 70% of the WCD prescribing universe. This rapid buildout enabled both deeper penetration of existing accounts and activation of new prescribers, with ordering facilities up 65% and new prescribers up 55%. The company plans to add another 40 reps in FY27, pacing expansion to balance ramp productivity and coverage optimization.
2. Clinical Evidence and Guideline Influence
Publication of the ACE-PASS study and recognition in Heart Rhythm Society guidelines reinforced the Assure system’s clinical value, catalyzing broader adoption. Kestra’s clinical evidence strategy focuses on publishing real-world outcomes and algorithm advancements, with multiple manuscripts and abstracts planned for the coming year. This approach aims to influence future clinical guidelines and expand the addressable market.
3. Revenue Cycle Management and Payer Mix
Kestra’s RCM enhancements and payer contracting have driven a higher in-network mix (low to mid 80%), improving revenue per prescription and collections. Investments in AI-based automation are expected to further increase efficiency, reduce denials, and support ongoing gross margin expansion as the business scales.
4. Product Innovation and Competitive Differentiation
Continuous product innovation—such as the new Assure detection algorithm and BioBeat collaboration—extends Kestra’s clinical differentiation. The company is shipping all new devices with the enhanced algorithm and is developing pipeline features that could further widen the competitive gap. Management views the incumbent’s new product as incremental, not transformative, and expects its own innovation to drive additional market share gains over the next three to five years.
5. Financial Flexibility and M&A Optionality
The new $200 million term loan facility with Pharmacon strengthens Kestra’s balance sheet and reduces cost of capital by 24% versus prior arrangements. With $357 million in liquidity, the company has the flexibility to invest in commercial growth, expand its fleet, and pursue tuck-in acquisitions that leverage its direct-to-cardiology channel.
Key Considerations
FY26 was a foundational year, marked by aggressive investment in commercial infrastructure and RCM that is now translating into accelerating growth and margin improvement. Investors should monitor the pace of sales rep ramp, payer mix shifts, and the impact of upcoming clinical publications on guideline adoption and prescriber behavior.
Key Considerations:
- Operating Leverage Inflection: Margin and cash burn improvement signals operating leverage as commercial investments mature.
- Salesforce Ramp Dynamics: Recent headcount additions may drive lagged but accelerating growth as new reps reach productivity milestones.
- Guideline Influence Potential: ACE-PASS and Heart Rhythm endorsement could catalyze broader WCD adoption if incorporated into formal guidelines.
- Competitive Fleet Turnover: Incumbent’s new product rollout is expected to be gradual, limiting near-term competitive disruption.
Risks
Execution risk remains around the absorption and productivity ramp of newly hired sales reps, which could cause uneven growth if onboarding lags. Guideline adoption is a multi-year process, and immediate revenue impact from clinical publications may be gradual. Competitive responses, regulatory events affecting the broader medtech sector, and payer dynamics—especially around reimbursement rates—are important watchpoints for future quarters.
Forward Outlook
For FY27, Kestra guided to:
- Revenue of $137 million, representing 44% YoY growth
- Continued margin expansion, targeting 700bps improvement for the full year
Management expects:
- Prescription growth from deeper existing account penetration and new account activation
- Higher in-network payer mix and ongoing RCM improvements to further boost revenue per prescription
Second-half weighted growth is anticipated as newly hired sales reps reach full productivity, with operating leverage expected to become more pronounced in FY27 and beyond.
Takeaways
- Margin Expansion Validates Model: Ten straight quarters of gross margin gains underscore the scalability and attractive economics of Kestra’s rental-based business.
- Commercial and Clinical Levers Accelerate Growth: Rapid salesforce buildout, payer contracting, and clinical evidence are combining to drive both share gains and market expansion.
- Watch for Guideline Shift and Rep Productivity: Investors should focus on the pace of guideline adoption and the lagged impact of new sales territory productivity as key drivers of future upside.
Conclusion
Kestra’s Q4 capped a year of strategic investment and operational execution, with margin gains and accelerating adoption positioning the company as a category leader in WCD. With robust liquidity and a clear path to further margin expansion, Kestra enters FY27 focused on scaling its commercial and clinical advantages for sustained growth.
Industry Read-Through
Kestra’s performance signals a broader trend of technology-driven disruption in the cardiac device market, where clinical evidence and payer contracting are critical differentiators. The company’s ability to expand gross margin while scaling commercial reach highlights the value of rental-based medtech models with recurring revenue. Incumbents face structural challenges in rapidly upgrading fleets, suggesting that nimble innovators can capture share even in mature device categories. Sector-wide, expect increased focus on real-world outcomes, RCM automation, and direct-to-clinician engagement as core levers for growth and margin improvement.